滋肾调肝法治疗绝经后骨质疏松症的疗效观察

Observation on the therapeutic effect of the treatment of nourishing kidney and accommodating liver on postmenopausal osteoporosis

目的探讨绝经后骨质疏松症的中医治疗方法。方法在山东省寿光市中医医院骨科门诊2015年3月~2016年3月就诊的绝经后骨质疏松症患者中,选出符合研究纳入标准的患者120例,分为滋肾调肝组(治疗组60例)、雷洛昔芬组(对照组60例),对治疗前后各组骨密度、骨代谢指标及安全性指标,治疗后的疗效评分进行对比。结果骨密度分析及疗效评价方面,治疗组及对照组在各个治疗周期内均较治疗前有明显好转,两组之间比较未显示出明显差异;安全性指标方面两组治疗前后及治疗期间内比较,差异无统计学意义,但治疗组在降低D-二聚体(P<0.05)、改善骨代谢指标(P<0.05)方面比对照组更有优势。结论滋肾调肝法治疗绝经后骨质疏松症疗效与雷洛昔芬无显著性差异,可使深静脉血栓风险减少,是治疗绝经后骨质疏松症的合理选择。

Objective To explore the Chinese medicine treatment for postmenopausal osteoporosis. Methods A total of 120 cases who met the research standards among the postmenopausal osteoporosis patients in orthopedic clinic of our hospital from March 2015 to March 2016 were selected. The patients were divided into nourishing kidney and accommodating liver group （treatment group） with 60 cases and raloxifene group （control group） with 60 eases .The bone density, bone metabolic index, safety index and treatment score between the two groups were compared before and after treatment. Results The treatment group and the control group were significantly improved in the bone density analysis and efficacy evaluation in every treatment cycle compared with those before treatment,with no significant difference between the two groups. There was no statistically significant difference between the two groups in terms of safety parameters before and after treatment and during treatment. But the treatment group had more advantages in reducing Ddimer （P〈0.05） and improving bone metabolism indicators （P〈0.05） than the control group. Conclusion The nourishing kidney and accommodating liver treatment has no significant difference with raloxifene in the treatment effect on postmenopausal osteoporosis, and its risk of deep venous is reduced, making it a reasonable choice for the treatment of postmenopausal osteoporosis.